Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewDQP 1105 is a noncompetitive NMDA receptor antagonist; displays over 50-fold selectivity for GluN2D- and GluN2C-containing receptors over GluN2B-, GluK2-, GluA1- and GluN2A-containing receptors (IC50 values are 2.7, 8.5, 121, 153, 198 and 206 μM, respectively). Reduces frequency of channel opening.
Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.
DQP 1105 is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.
M. Wt | 558.42 |
Formula | C29H24BrN3O4 |
Storage | Store at -20°C |
Purity | ≥97% (HPLC) |
CAS Number | 380560-89-4 |
PubChem ID | 2723792 |
InChI Key | JIQFFACVQXXHMY-YDALLXLXSA-N |
Smiles | O=C2C(C4=NN(C(CCC(O)=O)=O)C(C5=CC=C(Br)C=C5)C4)=C(C3=CC=CC=C3)C1=CC(C)=CC=C1N2 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 55.84 | 100 |
The following data is based on the product molecular weight 558.42. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.79 mL | 8.95 mL | 17.91 mL |
5 mM | 0.36 mL | 1.79 mL | 3.58 mL |
10 mM | 0.18 mL | 0.9 mL | 1.79 mL |
50 mM | 0.04 mL | 0.18 mL | 0.36 mL |
References are publications that support the biological activity of the product.
Acker et al (2011) Mechanism for noncompetitive inhibition by novel GluN2C/D N-MthD.-aspartate receptor subunit-selective modulators. Mol.Pharmacol. 80 782 PMID: 21807990
If you know of a relevant reference for DQP 1105, please let us know.
Keywords: DQP 1105, DQP 1105 supplier, DQP1105, supplier, NMDAD, Glu2NC, antagonists, selective, noncompetitive, inhibitors, inhibits, NMDA, Receptors, 4491, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for DQP 1105 include:
Brancaccio et al (2017) Astrocytes Control Circadian Timekeeping in the Suprachiasmatic Nucleus via Glutamatergic Signaling. Neuron 93 1420 PMID: 28285822
Lozovaya et al (2014) Selective suppression of excessive GluN2C expression rescues early epilepsy in a tuberous sclerosis murine model. Nat Commun 5 4563 PMID: 25081057
Do you know of a great paper that uses DQP 1105 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review DQP 1105 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.